Q2 2025 13F Holders as of 6/30/2025
-
Type / Class
-
Equity / Common Stock, $0.01 par value
-
Shares outstanding
-
7.19M
-
Number of holders
-
12
-
Total 13F shares, excl. options
-
219K
-
Shares change
-
-144K
-
Total reported value, excl. options
-
$127K
-
Value change
-
-$84.5K
-
Number of buys
-
6
-
Number of sells
-
-9
-
Price
-
$0.58
Significant Holders of NovaBay Pharmaceuticals, Inc. - Common Stock, $0.01 par value (NBY) as of Q2 2025
18 filings reported holding NBY - NovaBay Pharmaceuticals, Inc. - Common Stock, $0.01 par value as of Q2 2025.
NovaBay Pharmaceuticals, Inc. - Common Stock, $0.01 par value (NBY) has 12 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 219K shares
of 7.19M outstanding shares and own 3.04% of the company stock.
Largest 10 shareholders include C2C Wealth Management, LLC (98K shares), GEODE CAPITAL MANAGEMENT, LLC (33.8K shares), Rangeley Capital, LLC (33.2K shares), TWO SIGMA SECURITIES, LLC (24.3K shares), XTX Topco Ltd (20.3K shares), Tower Research Capital LLC (TRC) (5.45K shares), UBS Group AG (3.39K shares), BANK OF AMERICA CORP /DE/ (55 shares), NVWM, LLC (3 shares), and MORGAN STANLEY (3 shares).
This table shows the top 12 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.